India's Panacea Biotec to produce 100 mln Sputnik V doses annually -RDIF
05/04/2021 13:00
MOSCOW, April 5 (Reuters) - Indian biotech firm Panacea
Biotec Ltd PNCA.NS has agreed to produce 100 million doses of
Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct
Investment Fund (RDIF), which markets the shot internationally,
said on Monday.
RDIF did not say when production would begin.
(Reporting by Vladimir Soldatkin; Writing by Alexander Marrow,
ediitng by Emelia Sithole-Matarise)
((alexander.marrow@thomsonreuters.com;))
Recent news on Panacea Biotec
See all newsBrief: Panacea Biotec Receives Letter Of Award For BOPV Supply Worth $8.205 Million
Brief: Panacea Biotec Unit Gets Show Cause Notice Alleging Total Tax Liability Of 40.6 Million Rupees
Brief: Panacea Biotec Files Appeal Against Fourth Industrial Tribunal (Mohali) Award
India's Panacea Biotec rises to record high on EU-backed dengue vaccine project
India Stocks: Indian shares rise as banks gain on RBI forex swap facility